73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
73%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
73%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Nektar Therapeutics
Open
36.96 -0.27
Overview
Share price change
24h
Min
35.8
Max
37.06
Income | 6.1M -36M |
|---|---|
Sales | 615K 12M |
EPS | -1.87 |
Profit margin | -301.289 |
Employees | 61 |
EBITDA | 6.9M -29M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +179.47% upside |
Next Earnings | 11 Mar 2026 |
|---|
Market Cap | -373M 766M |
|---|---|
Previous open | 37.23 |
Previous close | 36.96 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Nektar Therapeutics Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Nektar Therapeutics Forecast
Price Target
By TipRanks
179.47% upside
12 Months Forecast
Average 103.71 USD 179.47%
High 135 USD
Low 30 USD
Based on 8 Wall Street analysts offering 12 month price targets forNektar Therapeutics - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
Live chat